Nordic Capital Bidding for Cinven's Sebia
Nordic May Combine Sebia With Other Medical Technology Firm
By SIMON CLARK
May 29, 2014 10:25 a.m. ET
LONDON—Nordic Capital is bidding for Sebia, a French medical diagnostics company owned by private-equity firm Cinven, according to people familiar with the situation.
Carlyle Group CG +0.66% LP and other private equity firms are also considering bids for the company, the people said.
Nordic Capital, based in Stockholm, jointly owns medical technology company ConvaTec with Avista Capital Partners. It may combine the two medical companies if the bid for Sebia is successful, the people said.
ConvaTec had €1.26 billion ($1.7 billion) of sales in 2013. Nordic Capital and Avista bought the company from Bristol-Myers Squibb Co. BMY 0.00% in 2008. After that acquisition, ConvaTech integrated Unomedical, a medical company that Nordic Capital had owned since 2003.
Cinven bought Sebia from Montagu Private Equity in 2010. Sebia, based south of Paris, increased its sales by 4.7% in the first half of 2013 to €78.3 million.
Nordic May Combine Sebia With Other Medical Technology Firm
By SIMON CLARK
May 29, 2014 10:25 a.m. ET
LONDON—Nordic Capital is bidding for Sebia, a French medical diagnostics company owned by private-equity firm Cinven, according to people familiar with the situation.
Carlyle Group CG +0.66% LP and other private equity firms are also considering bids for the company, the people said.
Nordic Capital, based in Stockholm, jointly owns medical technology company ConvaTec with Avista Capital Partners. It may combine the two medical companies if the bid for Sebia is successful, the people said.
ConvaTec had €1.26 billion ($1.7 billion) of sales in 2013. Nordic Capital and Avista bought the company from Bristol-Myers Squibb Co. BMY 0.00% in 2008. After that acquisition, ConvaTech integrated Unomedical, a medical company that Nordic Capital had owned since 2003.
Cinven bought Sebia from Montagu Private Equity in 2010. Sebia, based south of Paris, increased its sales by 4.7% in the first half of 2013 to €78.3 million.